CARD9, VAV3, and infection risk in IgA nephropathy

肾病 内科学 医学 人口 安慰剂 随机对照试验 免疫学 蛋白尿 胃肠病学 肾 病理 内分泌学 糖尿病 替代医学 环境卫生
作者
Patrick J. Gleeson,Harry Sokol,Renato C. Monteiro
出处
期刊:Kidney International [Elsevier BV]
卷期号:103 (5): 996-997 被引量:3
标识
DOI:10.1016/j.kint.2023.02.013
摘要

The risk of opportunistic infection reported from trials of systemic immunosuppression for IgA nephropathy (IgAN) is higher than the risk expected in a general rheumatology population. 1 Park J.W. Curtis J.R. Moon J. et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018; 77: 644-649 Crossref PubMed Scopus (160) Google Scholar In Part A of the Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (NefIgArd) trial, Barratt et al. report no increased risk of infection with the use of local gut-targeting corticosteroids that have minimal systemic absorption, while still achieving reductions in proteinuria similar to those seen with systemic therapy. 2 Barratt J. Lafayette R. Kristensen J. et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023; 103: 391-402 Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathyKidney InternationalVol. 103Issue 2PreviewThe therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. To verify these findings, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon (16 mg/d) versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure (ClinicalTrials.gov: NCT03643965 ). NefIgArd was a multicenter, randomized, double-blind, placebo-controlled two-part trial. Full-Text PDF Open AccessThe authors replyKidney InternationalVol. 103Issue 5PreviewWe read with interest the correspondence from Gleeson and colleagues discussing the potential genetic predisposition of patients with IgA nephropathy (IgAN) to opportunistic infections, especially during treatment with systemic glucocorticoids.1 A takeaway from these observations is that prior to treating IgAN patients with a systemic glucocorticoid, stratifying by genetic risk, to avoid serious complications, may be a good idea. One of the main motivations for developing Nefecon for IgAN treatment has been to provide a new tool for effective treatment that has far less toxicity than the immunomodulatory agents typically used, especially prednisone/prednisolone. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
neuro1993发布了新的文献求助20
1秒前
乐空思的应助被cyanberg采纳,获得20
2秒前
2秒前
项阑悦完成签到,获得积分10
2秒前
傅凯完成签到,获得积分10
4秒前
奔跑石小猛完成签到,获得积分10
6秒前
111发布了新的文献求助20
7秒前
思源的应助被简qw采纳,获得10
8秒前
叮叮当完成签到 ,获得积分10
10秒前
小二郎的应助被七月流火采纳,获得30
11秒前
踏实的代曼完成签到,获得积分10
12秒前
My完成签到,获得积分10
12秒前
13秒前
13秒前
开朗真完成签到 ,获得积分10
13秒前
现代宛丝完成签到,获得积分10
14秒前
neuro1993完成签到,获得积分20
14秒前
科研通AI6.3的应助被外向板栗采纳,获得10
16秒前
111完成签到,获得积分10
16秒前
晴天完成签到 ,获得积分10
16秒前
冯亦帆帆发布了新的文献求助10
17秒前
Juvenilesy的应助被自然醒采纳,获得10
19秒前
菘蓝完成签到 ,获得积分10
19秒前
现代宛丝发布了新的文献求助10
19秒前
20秒前
ry关闭了ry的文献求助
21秒前
马赛克完成签到,获得积分10
21秒前
七听的应助被hhhhh采纳,获得150
22秒前
myfmmmm完成签到,获得积分20
22秒前
ferrumNjr完成签到,获得积分10
22秒前
Yee完成签到 ,获得积分10
22秒前
bkagyin的应助被jgz1215采纳,获得10
22秒前
微7完成签到,获得积分10
23秒前
23秒前
田様的应助被vamcello采纳,获得10
24秒前
满意的妙海完成签到 ,获得积分10
24秒前
简qw发布了新的文献求助10
24秒前
孙栗吱完成签到 ,获得积分10
25秒前
25秒前
薄荷完成签到 ,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552